1. Home
  2. USBC vs IMMX Comparison

USBC vs IMMX Comparison

Compare USBC & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USBC Inc.

USBC

USBC Inc.

N/A

Current Price

$0.69

Market Cap

333.2M

Sector

N/A

ML Signal

N/A

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$5.68

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USBC
IMMX
Founded
N/A
2014
Country
United States
Employees
6
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
333.2M
306.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
USBC
IMMX
Price
$0.69
$5.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
N/A
1.4M
Earning Date
N/A
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.34
52 Week High
N/A
$7.73

Technical Indicators

Market Signals
Indicator
USBC
IMMX
Relative Strength Index (RSI) 40.94 55.86
Support Level $0.68 $5.46
Resistance Level $0.74 $6.09
Average True Range (ATR) 0.06 0.70
MACD -0.00 -0.13
Stochastic Oscillator 10.04 36.38

Price Performance

Historical Comparison
USBC
IMMX

About USBC USBC Inc.

USBC Inc is a non-invasive medical diagnostics. The group is focused on the development and commercialization of proprietary sensor technology utilizing radio and microwave dielectric spectroscopy. Its Sensor technology elicits a dielectric response that is different for every molecule. The group considers the business to currently have one operating segment: the development of its radio frequency spectroscopy technology, with a first focus on non-invasively ascertaining blood glucose levels.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: